Adelis-backed SSI Diagnostica to acquire CTK Biotech.

Adelis-backed SSI Diagnostica, a biotechnology company, agreed to acquire CTK Biotech, a developer and distributor of diagnostic rapid tests. Financial terms were not disclosed. "We have been planning for this acquisition for a long time. We have been looking for a partner who is great at diagnostic rapid tests in infectious diseases and has technology and competencies in monoclonal antibodies. We have found the perfect match in CTK Biotech. Our companies complement each other extremely well," Patrik Dahlen, SSI CEO.